(Q81420892)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15721449%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

title

Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15721449%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

1 reference

1

Bradley J Monk

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15721449%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

David C Choi

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15721449%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Gordon Pugmire

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15721449%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Robert A Burger

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15721449%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

publication date

1 March 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15721449%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15721449%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

96

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15721449%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

902-905

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15721449%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15721449%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

cites work

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.001

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.001

Angiogenesis in epithelian ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.001

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.001

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.001

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.001

Remaining controversies in the upfront management of advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.001

Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.001

10.1016/J.YGYNO.2004.12.001

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15721449%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference